LAS VEGAS, June 5, 2013 /PRNewswire/ -- PharmaRoth
Labs, Inc. (OTCPink: ROTH), the exclusive producer, marketer &
distributor of Sucanon®, an oral Type-II Diabetes treatment, is
pleased to introduce the two newest members of the Company's Board
of Advisors, Dr. Jose Alberto Rojas
Jimenez and Dr. Alberto Meraz
Soria. Dr. Rojas Jimenez
recently concluded a clinical trial of Sucanon® on 98 Hispanic
pre-diabetic patients, and the findings of the study are to be
presented at the European Association for the Study of Diabetes
Annual Meeting in Barcelona, Spain
on September 23-27, 2013.
Dr. Rojas Jimenez is a graduate
of the prestigious School of Medicine of the Autonomous University
of San Luis Potosi. He is Board
certified in Internal medicine. His affiliations and membership
include: The American British Cowdray Medical Center, American
College of Physicians, European Association for the Study of
Diabetes, the American Diabetes Association and board member of the
Morbi-mortality Health System Federal District. Dr. Rojas Jimenez is a pioneer in the area of
ambulatory continuous glucose monitoring as a diagnostic tool in
Mexico. He also belongs to the
Speakers Bureau of Eli Lilly Mexico, AMK Health Care and P&G.
As an expert in Diabetes, he has given over 350 presentations over
the past 5 years.
Dr. Meraz Soria also graduated
from the School of Medicine of San Luis
Potosi, and he is Board Certified in Internal Medicine. Dr.
Meraz Soria specialized in Critical
Condition patients where he received honorific mention. He is
affiliated with the Emergency Service Hospital Sante Fe and a
deputy at ABC Pulmonary Physiology and Inhalotherapy Hospital. Dr.
Meraz Soria also completed clinical
course work thru the Clinical Diabetology Steno Group in
Copenhagen, Denmark. Dr.
Meraz Soria is coordinating the
design and implementation of the new clinical trial that will start
in the last quarter of this year.
"I am extremely proud to announce the addition of Drs.
Rojas Jimenez and Meraz Soria to our Board of Advisors," stated
Luis Lopez, CEO of PharmaRoth. "Both
men are highly renowned and have made significant contributions to
the medical communities. In addition, Dr. Rojas Jimenez's clinical trial with Sucanon®
adds to the growing body of evidence that our product exceeds
expectations not just in the stabilization of blood glucose, but
also could be used as an alternative for metabolic syndrome that
includes reduction in visceral body fat without any
side-effects."
About
Sucanon®
Sucanon® is
approved as an OTC treatment for Type-II diabetes by regulatory
authorities in Mexico, containing
natural ingredient. It is one of only three approved drugs in the
multi-billion dollar market for a class of diabetic medications
called "insulin sensitizers". Pre-clinical and clinical
studies conducted ex-US have shown that Sucanon® and
other insulin sensitizers lower a patient's blood sugar by
increasing the muscle, fat and liver's sensitivity to the body's
own naturally produced insulin.
For further information regarding Sucanon®, please
visit PharmaRoth Labs, Inc. website at http://pharmaroth.com/
About PharmaRoth Labs
Inc.
PharmaRoth Labs, Inc. (ROTH) is
focused on diabetes prevention and treatments. The Company
holds the intellectual property and all exclusive world-wide rights
related to the production, marketing, and distribution of
Sucanon®, an oral treatment for Type-II diabetes.
Sucanon® is a member of a class of diabetic medications
called insulin sensitizers. Insulin sensitizers lower blood
sugar by increasing the muscle, fat and liver's sensitivity to
insulin. Insulin sensitizers are blood sugar normalizing or
euglycemic drugs that help return the blood sugar to the normal
range without the risk of low blood sugars. PharmaRoth's
strategy is to increase awareness, acceptance, and distribution of
Sucanon® globally.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements are based on the current plans and expectations of
management and are subject to a number of uncertainties and risks
that could significantly affect the company's current plans and
expectations, as well as future results of operations and financial
condition. The company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contact and Inquiries for Investor Relations:
Michael Irving
Paramount Advisors, LLC
407-878-5462
mike@parvise.com
SOURCE PharmaRoth Labs, Inc.